The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | The role of selinexor in the context of novel immune therapies in R/R multiple myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, comments on the use and benefits of selinexor in relapsed/refractory (R/R) multiple myeloma. Prof. Mohty explains that this oral and effective agent should still be considered in specific patient populations, even in the context of new immune therapies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead: Honoraria; GSK: Honoraria; Pfizer; Honoraria; Adaptive Biotechnologies: Honoraria; Oncopeptides: Honoraria; Astellas: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Amgen: Honoraria; Jazz Pharmaceuticals: Honoraria, Research Funding; Celgene: Honoraria; Bristol Myers Squibb: Honoraria; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.
